Pharmaceutical company Novartis AG invested $9.996 billion in Research and Development in 2022, an increase of 4.8% year-on-year. In April 2022, the company announced the
Mexico‘s Federal Economic Competition Commission (Cofece) granted Procaps Group antitrust regulatory approval for the acquisition of Grupo Somar and Pearl Mexico. Cofece’s approval allows Procaps
On August 6, 2020, Bausch + Lomb announced the plan to separate its eye health business, consisting of its Bausch + Lomb Global Vision Care
The pharmaceutical company Novartis will invest 50 million dollars in clinical research in Mexico in the next triennium. All drug candidates undergo proof-of-concept trials to
Pharmaceutical company Novartis AG invested $9.996 billion in Research and Development in 2022, an increase of 4.8% year-on-year. In April 2022, the company announced the
Mexico‘s Federal Economic Competition Commission (Cofece) granted Procaps Group antitrust regulatory approval for the acquisition of Grupo Somar and Pearl Mexico. Cofece’s approval allows Procaps
On August 6, 2020, Bausch + Lomb announced the plan to separate its eye health business, consisting of its Bausch + Lomb Global Vision Care
The pharmaceutical company Novartis will invest 50 million dollars in clinical research in Mexico in the next triennium. All drug candidates undergo proof-of-concept trials to
